drugset / Trial / NCT07003919
Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)
RandomizedParallel-groupTriple-blindTreatment
Summary
The primary objective of this study is to assess the 6-month safety of DBV712 250 micrograms (mcg) in subjects 1 through 3 years of age with peanut allergy.
Timeline
- Start
- 2025-06-24
- Primary completion
- 2026-11
- Completion
- 2028-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DEFATTED POWDER OF ARACHIS HYPOGAEA L., SEMEN (PEANUTS) | Protein / enzyme biologic | 250 ug | Topical |